Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Palo Alto Networks Inc (PANW) Price & Performance

AbCellera Biologics IncTrade
Palo Alto Networks IncTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Palo Alto Networks Inc — how do they compare? AbCellera Biologics Inc trades at $9.99 (market cap $2.99B), while Palo Alto Networks Inc trades at $384.52 (market cap $312.80B). The key difference: Palo Alto Networks Inc is far larger — about 104.6× AbCellera Biologics Inc's market cap. Which is the better fit depends on your goals.

ABCLPANW
Market Cap
$2.99B$312.80B
Sector
HealthTechnology
52-Week High
$9.76$385.04
52-Week Low
$2.78$141.67
Enterprise Value
$2.58B$311.76B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.

The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.

Palo Alto Networks Inc

Palo Alto Networks (PANW) trades at $384.29, down 0.19% on the day, with a bullish technical signal supported by moving averages and strong institutional sentiment. Revenue grew to $9.22B in FY2025, with net income of $1.13B, though valuation ratios like P/E of 333.74 and P/S of 26.64 appear elevated. Recent news highlights AI-driven cybersecurity demand and a China regulatory review, while the company beat EPS estimates in three consecutive quarters.

Outlook remains positive due to robust AI security growth and analyst consensus, but risks include high valuation, integration costs from acquisitions, and geopolitical scrutiny. The stock's proximity to its 52-week high suggests cautious optimism, with upside potential tied to execution on AI initiatives and cybersecurity spending trends.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Palo Alto Networks Inc

Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.

Read more on PANW